Navigation Links
Eloxatin (oxaliplatin injection)-Based Chemotherapy Sets New,Treatment Benchmark in Patients With Metastatic Colorectal Cancer

FOLFOX4 Chemotherapy Results in Improved Long-term [Five-years] Overall Survival for these Seriously Ill Patients

CHICAGO, June 04, 2007 /PRNewswire-FirstCall/ -- FOLFOX4, an Eloxatin(R)-based chemotherapy regimen, provided significant improvements in long-term [five- years] overall survival (OS) and time to disease progression (TTP) - a longer period of stable disease - in patients with metastatic (advanced) colorectal cancer. Importantly, the FOLFOX4 results were significantly better than those achieved with irinotecan-based chemotherapy, known as IFL, and IROX, a combination of irinotecan and Eloxatin(R). These data were presented today at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago in an updated analysis of the N9741 study.

FOLFOX4 (Eloxatin(R) combined with infusional 5-FU/LV) was established in the United States as first line treatment for advanced colorectal cancer after the initial presentation of the N9741 study results in 2003 and subsequent Food and Drug Administration (FDA) approval in January 2004. The updated analysis confirms the earlier results and identifies FOLFOX4 chemotherapy as the strongest predictor of improvement in both overall survival and time to disease progression.

N9741 Five-Year Analysis

This study evaluated several chemotherapy regimens using various combinations of Eloxatin(R), 5-FU/LV and irinotecan in 1,691 previously untreated patients with metastatic colorectal cancer who were randomized to seven arms.

Metastatic colorectal cancer patients given the Eloxatin(R)-based regimen FOLFOX4 were almost twice as likely to survive at least five years as those on irinotecan-based therapy (IFL). Five-year survival and time-to-progression rates were calculated using Kaplan-Meier methods for each treatment arm. Patients treated with FOLFOX4 had a 9.2% overall chance of surviving for five years after treatment, the best
'"/>




Page: 1 2 3 4

Related medicine technology :

1. The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved Progression Free Survival When Given Before and After Surgery in Patients With Resectable Liver Metastases From Colorectal Cancer
2. Pharmacyclics Announces Interim Results From Two Ongoing Phase 2 Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat Recurrent Non-Small Cell Lung Cancer
3. July Issue of Journal of Antimicrobial Chemotherapy Highlights Study of Factive Tablets for Five-Day Treatment of Community-Acquired Pneumonia
4. New Data Show Pfizers Axitinib Prolonged Overall Survival in Advanced Pancreatic Cancer When Combined with Standard of Care Chemotherapy
5. Hyperthermia Plus Chemotherapy Nearly Doubles Disease-Free Survival Compared to Chemotherapy Alone for Sarcoma Cancer Patients
6. Promising Results with Epratuzumab and Chemotherapy in Children with Acute Lymphoblastic Leukemia
7. MabThera Significantly Extends Survival And Cures More Patients With Aggressive Lymphoma Than Chemotherapy Alone
8. Prostate Cancer: Clinical Study Demonstrates Superior Efficacy of Docetaxel Chemotherapy
9. MabThera Significantly Increases Survival of Lymphoma Patients Regardless of Chemotherapy Regimen
10. Abraxis BioScience Presents Data from Pre-Clinical Study That Provide Evidence for Chemotherapy-Induced Angiogenesis and Rationale for Combining nab-Paclitaxel (Abraxane) with Anti-Angiogenic Agents to Increase Tumor Response
11. Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual Meeting
Post Your Comments:
(Date:1/15/2014)... Jan. 15, 2014  Manufacturers, suppliers and distributors of ... to protect their most important business assets, intellectual ... ) Because of the highly-competitive nature ... one of the most litigious industry sectors of ...
(Date:1/15/2014)... MultiCell Technologies, Inc. (OTC Bulletin Board: ... concerning composition of matter, biological targets, mechanism of action, ... This patent application describes a novel ... (VSRNAs) which interfere with the basic homeostatic cellular processes ...
(Date:1/15/2014)... to Millennium Research Group (MRG), the global authority ... United States and European transcatheter embolization ... through 2022, with embolization particles representing one of ... drug-eluting beads (DEBs) and radioembolization spheres in interventional ...
Breaking Medicine Technology:Intellectual Property Insurance for Medical-related Products and Services 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3
... ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA ), today ... 2010.  Third quarter 2010 net revenues were $42.0 million, ... 2009.  Excluding the recognition of one-time license revenue in ... 44%.  Net loss for the third quarter ended September ...
... 2, 2010 Cannabis Science, Inc. (OTC Bulletin Board: ... cannabis products, is pleased to announce to its shareholders and ... decisions and processes regarding the new class of common shares. ... 1 for 10 new share dividend payment for shareholders of ...
Cached Medicine Technology:ISTA Pharmaceuticals Reports Third Quarter 2010 Financial Results 2ISTA Pharmaceuticals Reports Third Quarter 2010 Financial Results 3ISTA Pharmaceuticals Reports Third Quarter 2010 Financial Results 4ISTA Pharmaceuticals Reports Third Quarter 2010 Financial Results 5ISTA Pharmaceuticals Reports Third Quarter 2010 Financial Results 6ISTA Pharmaceuticals Reports Third Quarter 2010 Financial Results 7ISTA Pharmaceuticals Reports Third Quarter 2010 Financial Results 8ISTA Pharmaceuticals Reports Third Quarter 2010 Financial Results 9ISTA Pharmaceuticals Reports Third Quarter 2010 Financial Results 10Cannabis Science Announces a Proposed 10:1 Ratio Structured Dividend Payout for a New Class of Common Shares to Shareholders of Record as of November 30, 2010 2Cannabis Science Announces a Proposed 10:1 Ratio Structured Dividend Payout for a New Class of Common Shares to Shareholders of Record as of November 30, 2010 3
(Date:4/17/2014)... pain relief targets that could be used to ... King,s College London made the discovery when researching ... of the body. , Dr Marzia Malcangio said: ... pain generation and our findings could help chemotherapy ... One potential side effect of some chemotherapy drugs ...
(Date:4/17/2014)... School of Medicine report that older women, plucky individuals ... are more likely to be compassionate toward strangers than ... this month,s issue of the International Journal of ... with better health and well-being as we age, the ... outcomes of individuals whose deficits in compassion put them ...
(Date:4/17/2014)... has created a new technology for modifying human ... the body and selectively target cancer and other ... that monitor and modify human physiology is a ... existing technology enabled bioengineers to build such devices ... in a customized fashion. , "The project addressed ...
(Date:4/17/2014)... NY (April 16, 2014) The cause of neuronal ... new study proposes that neurons may be mistaken for ... system, similar to the way autoimmune diseases like type ... body,s cells. The study was published April 16, 2014, ... new, and likely controversial, idea in Parkinson,s disease; but ...
(Date:4/17/2014)... April 17, 2014 EcoHealth Alliance, a nonprofit ... issues, published a comprehensive review today examining the current ... virus. The review calls for improved global surveillance strategies ... the recent outbreak of Ebola in West Africa that ... countries of Guinea and Liberia. According to the ...
Breaking Medicine News(10 mins):Health News:New pain relief targets discovered 2Health News:The ilk of human kindness 2Health News:Building 'smart' cell-based therapies 2Health News:Is Parkinson's an autoimmune disease? 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 3
... Oct. 7 All American gymnast, wife and mom-to-be Shannon ... expecting her first baby in late October and has been ... best possible start on life and learning. Now she,s ... moms around the world. , (Photo: http://www.newscom.com/cgi-bin/prnh/20091007/DE88885 ...
... suspect , WEDNESDAY, Oct. 7 (HealthDay News) -- Younger people ... an anterior cruciate ligament repaired, a new study has ... commonly called an ACL. , ACL damage is one of ... data from more than 70,000 people in New York who ...
... those with, without device , WEDNESDAY, Oct. 7 (HealthDay News) ... heart attack does not improve survival, a major European study ... those given the devices, which shock the heart into beating ... as for those who did not get defibrillators in the ...
... Global TV Concepts, manufacturer and creator of the ... World Record title for the ,World,s Largest Cupcake., Weighing ... feet tall and six feet wide, the massive cupcake was ... from slices of the confectionary masterpiece supported breast cancer charities. ...
... Company,s (NYSE: CRDA ; CRDB) European third party ... name of Broadspire, a Crawford company, continuing the leading ... CRDA ; CRDB), the world,s largest independent provider ... the Broadspire brand at the Federation of European Risk ...
... US Farms, Inc. (Pink Sheets: USFM) today announced that it ... ( www.edisastersystems.com ) based out of City of ... , Yan Skwara, CEO for US Farms, Inc. ... and soothing burns and having our Aloe365(TM) Skin Gel registered ...
Cached Medicine News:Health News:Country's Most Decorated Gymnast New Spokesmom for BabyPlus 2Health News:2nd Knee Surgery Common Among Young Patients 2Health News:Early Defibrillator After Heart Attack May Not Pay Off 2Health News:Early Defibrillator After Heart Attack May Not Pay Off 3Health News:Big Top Cupcake(TM) Brand Awarded With Guinness World Record For World's Largest Cupcake 2Health News:Crawford & Company's Broadspire Unit Continues Its European Expansion 2Health News:US Farms, Inc. Becomes a Registered Seller of Its Aloe365(TM) Skin Gel With Emergency Disaster Systems, Inc. 2Health News:US Farms, Inc. Becomes a Registered Seller of Its Aloe365(TM) Skin Gel With Emergency Disaster Systems, Inc. 3Health News:US Farms, Inc. Becomes a Registered Seller of Its Aloe365(TM) Skin Gel With Emergency Disaster Systems, Inc. 4
Skin Tone External Eyelid Weights...
To prevent retraction of the conjunctival cul-de-sacs without touching the cornea....
Zone Quick is a simple and accurate system that measures tear volume in just 15 seconds per eye. Each box has an easy to read diagnostic indicator rule....
... Stent has been introduced by FCI Ophthalmics, Inc. ... Lacrimal Stent addressed the limitations previously encountered with ... DCR. Brought in to position through the nose, ... is no need to pass the very large ...
Medicine Products: